Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ST8 ADC
- Development stage
- Preclinical
- Lead developer
- IntoCell
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ST8 ADC is an antibody-drug conjugate (ADC) being developed by IntoCell for the treatment of solid cancers. The therapeutic candidate consists of a monoclonal antibody targeting the ST8 antigen, which is expressed on the surface of various tumor cells, conjugated to a cytotoxic payload. ST8 ADC utilizes IntoCell's proprietary linker technology, likely including their OHPAS (Orthogonal Hydroxyl Protected Azido-Silyl) platform, which is designed to improve the stability of the conjugate in systemic circulation and facilitate the selective release of the payload upon internalization into target cells. By delivering the cytotoxic agent directly to ST8-expressing malignancies, the drug aims to maximize anti-tumor efficacy while minimizing off-target toxicity. It is currently in preclinical development.
- Other names
- IntoCell ST8 ADC
02
Targets
ST8SIA2 (ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2)
Beyond the preview
Go deeper on ST8 ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ST8 ADC.